Kornimate/medical-research-clean huggingface dataset:
serum lipid levels and other biomarkers of cardiovascular disease in patients with psoriasis

Conditions: Psoriasis; Cardiovascular Diseases; Dyslipidemia

Summary: psoriasis patients are known to be at increased risk for heart disease. this may be due to the increased prevalence of cardiovascular disease risk factors in this population, including high blood pressure, diabetes, obesity, and high cholesterol. although cholesterol levels are known to be altered in psoriasis, most studies have used standard lipid profiles to measure cholesterol. these tests indirectly measure ldl (bad cholesterol) and become less accurate when triglyceride levels are high, as often see in individuals with psoriasis. we have designed a case-control study that uses a more specific and detailed cholesterol test to measure serum lipid levels in psoriasis patients, allowing for more accurate determination of ldl and better assessment of the lipid-contribution to cardiovascular risk. we will also measure other markers of inflammation that may contribute to cardiovascular disease.


Eligibility criteria:
inclusion criteria: * adults of both sexes from our dermatology clinic, between the age 18 and 80 years who wish to participate voluntarily in the study and who have signed a written informed consent form to participate. cases will have a diagnosis of psoriasis as diagnosed by our principal investigator, while controls will be selected from the same dermatology clinic. exclusion criteria: * current or past use (within 6-8 weeks) of anti-hyperlipidemic agents (statins, fibrates, neomycin, niacin, ezetimibe) and/or any other medications significantly affecting lipid metabolism, including cyclosporine, acitretin, protease inhibitors, tamoxifen, clozapine, and estrogen replacement therapy. * presence of secondary causes of hyperlipidemia including diabetes mellitus, smoking, untreated hypothyroidism, nephrotic syndrome, chronic kidney disease, and cholestatic liver disease (e.g. primary biliary cirrhosis). * history of cardiovascular disease (e.g. previous myocardial infarction, stroke, or angioplasty performed secondary to atherosclerosis). * history of alcohol intake \>30 g/day in males and \>20 g/day in females. * pregnancy * subjects with conditions or diseases hindering data collection and follow up, such as incapacitating diseases, cognitive deterioration, institutionalized patients.

Keywords: psoriasis heart disease cardiovascular disease hyperlipidemia
comparison of ocular surface features in patients with diabetes and dry eye syndrome

Conditions: Dry Eye Syndrome; Diabetes Mellitus Type 2

Summary: the study aims to compare the differences of ocular surface features in controls and patients with diabetes and dry eye syndrome, to thoroughly evaluate the ocular surface health of diabetics, and to find out the relationship between dry eye syndrome and diabetes

in this study, we perform a completely comparison of ocular surface characteristic including the ocular surface disease index (osdi) questionnaire,tearfilm break up time(but),corneal fluorescein scores(cfs),shirmer test,corneal sensitivity)among diabetic patients with de, diabetic patients without de, non-diabetic patients with de and normal subjects and analysis of egf, il-17a, il-1β, il-8 and tnf-α in tears and their clinical correlations are also performed to investigate potential biomarkers for diagnosis of diabetic with de.

Eligibility criteria:
inclusion criteria: 1. dry eye diagnosis according to expert's consensus about clinical diagnosis and treatment（corneal disease group of ophthalmological society, chinese medical association）: ①osdi≥13，②positive dry eye soigns(st≤10mm/5min；but≤10s；cfs\>0) 2. type 2 diabetes diagnosis according to american diabetes association：standards of medical care in diabetes -2017(ada, american diabetes association) 3. willing to sign the consent form. exclusion criteria: 1. having known eye infection, allergy, malformation, abnormal eye movement 2. exclusion of eye injury, any kind of eye surgery 3. exclusion of other disease may cause neuropathy or influence tear producing 4. using systematic or local antibiotics that may influence tear producing elimianation criteria 1. poor compliance 2. voluntary withdrawal 3. any other kind of situation that researchers consider not suitable for further study.

Keywords: ocular surface
resource use and disease course in dementia (redic)

Conditions: Neurodegenerative Diseases; Dementia

Summary: this project is based on a three-year program that aims to improve the knowledge of the socioeconomic consequences of dementia in norway. by including patients with and without dementia in four different cohorts (from nursing homes, from memory clinics, home-dwelling persons with dementia and elderly persons without dementia), the project's aim is to describe the course of dementia, the economical cost of dementia and to look into possible risk factors for dementia.


Eligibility criteria:
memory clinic sample inclusion criteria: * all patients examined at a memory clinic with mild cognitive impairment or mild dementia exclusion criteria: * none in-home care sample inclusion criteria: * persons 70 years of age or older receiving in-home care from the municipality exclusion criteria: * none nursing-home sample inclusion criteria: * all persons admitted to the nursing home with an expected stay of more than four weeks. * participants should be 65 years or older, unless established dementia disease, in which case younger persons also will be included exclusion criteria: * life expectancy of less than six weeks control sample inclusion criteria: * persons 65 years or older without any sign of dementia exclusion criteria: * none

Keywords: health care costs genetic polymorphism
effects of active gamification on sleep and anxiety in primary school children

Conditions: Students; Metal Health

Summary: active gamification, which incorporates game elements with physical interaction, is presented as an innovative strategy to address anxiety problems and sleep quality in children. there is evidence to suggest that physical activity and structured play can positively influence emotional regulation and sleep hygiene, which makes it relevant to explore interventions based on this methodology within the educational field. this study aims to evaluate the impact of an active gamification program on these variables in children in primary education. to do so, a randomized controlled trial will be carried out with the participation of 120 children between 8 and 11 years of age. participants will be randomly assigned to one of two groups: an experimental group, which will participate in a program designed to promote physical activity through game dynamics for 12 weeks, and a control group, which will continue with traditional physical education classes without modifications to their usual methodology. the implementation of the program includes structured sessions with activities designed to encourage interaction, movement and decision-making within a playful environment, in order to enhance children's commitment and adherence to the intervention.


Eligibility criteria:
inclusion criteria: * age between 8 and 11 years * no medical contraindication for physical activity * no intellectual disability that could interfere with understanding or compliance with the study procedures; and iv) informed consent from parents or legal guardians. those students who did not meet the inclusion criteria were able to participate in the intervention with their peers, but were not considered in the analysis. exclusion criteria: * diagnosis of neuromotor disorder or severe physical disability that limits participation in the scheduled physical activity * presence of severe psychological or behavioral disorders that make integration into group activities difficult. * use of medication that significantly affects physical or cognitive performance. * failure to attend more than 20% of the intervention program sessions * withdrawal of informed consent by parents or legal guardians during the study
optimising cmr scan acquisitions for novel equipment/sequences in clinical cardiovascular populations.

Conditions: Heart Failure With Preserved Ejection Fraction

Summary: the purpose of this study is to develop robust protocols for the optimisation of novel hardware, software and exercise equipment in the magnetic resonance imaging (mri) environment in various cohorts with cardiovascular disease (cvd) with the first study focusing on those with established heart failure with preserved ejection fraction (hfpef) or those at risk of or with pre-hfpef.


Eligibility criteria:
inclusion criteria: * males or females aged \>18 years * either a clinical diagnosis of hfpef, be at risk of or pre- hfpef exclusion criteria: * absolute contraindication to mri * unable to read/understand english sufficiently to provide informed consent * pregnancy * unable to consent due to lack of mental capacity * current cancer diagnosis and actively undergoing treatment * inability to exercise on the mri ergometer * severe claustrophobia
mayo designed soft tissue ultrasound-detectable marker

Conditions: Breast Neoplasm Female; Ultrasound Therapy; Complications

Summary: researchers are trying to determine if the mayo marker is easily seen with ultrasound making it easier, faster, and more accurate for preoperative localization of the biopsied positive lymph node.

nonrandomized clinical trial to evaluate the mayo-designed marker for ultrasound conspicuity at the time of preoperative ultrasound-guided localization. study participants are breast cancer patients with pathology-proven metastatic axillary lymph nodes. per standard of care, a biopsy marker will have already been associated with the positive lymph node. 10 such patients scheduled for surgery at mayo clinic rochester, mn with dr. james jakub will be enrolled. preoperative radioactive seed localization will proceed as usual, but the marker will be additionally loaded with the seed into the needle using standard protocol. before surgery, ultrasound will be performed to evaluate the marker.

Eligibility criteria:
inclusion criteria: * patient 18 years or older with breast cancer and biopsy-proven malignant involvement of an axillary lymph node * surgical management involves preoperative radioactive seed localization of a previously identified positive axillary lymph node * surgery will be performed by dr. james jakub at mayo clinic rochester, mn * radioactive seed localization of an axillary lymph node. * no contraception is necessary or required. * english speaking exclusion criteria: * scheduled for only radioactive seed localizations in the breast (as opposed to axilla) * are pregnant; although the twinkling marker is made of material widely used in orthopedic procedures, and hence, has an excellent safety profile, the investigators want to exclude the population of pregnant patients in this phase 0 clinical trial.

Keywords: axillary lymph node biopsy clip biopsy marker ultrasound
does body mass index impact the outcome of dural puncture epidural in parturients undergoing normal vaginal delivery

Conditions: Morbid Obesity

Summary: recently, the dural puncture epidural (dpe) technique has emerged as a novel method of labor analgesia. the dpe technique is a modification of the combined spinal epidural (cse) technique, where a dural perforation is created from a spinal needle but intrathecal medication administration is withheld. the dpe technique has been shown to improve caudal spread of analgesia compared with epidural technique without the side effects observed with the cse technique.

investigators designed this prospective interventional study to determine if morbid obesity would influence dpe technique regarding labor analgesia onset and block characteristics.

Eligibility criteria:
inclusion criteria: 1. 18 - 45 years old, 2. physical status american society of anesthesiology (asa) ii, 3. singleton, 4. vertex fetuses at 37-41 weeks' gestation, 5. nulliparous and multiparous women, 6. immediately before epidural placement, subjects marked a vnrs score during an active contraction and parturients with vnrs ≥ 50 were included 7. cervical dilatation \< 5 cm exclusion criteria: 1. contraindications to regional anesthesia 2. refuse to participate 3. no pain 4. severe systemic disease (kidney, liver, pulmonary, endocrine, cardiac) 5. conditions associated with an increased risk of a cesarean delivery (i.e., history of uterine anomaly or surgery) and vaginal birth after cesarean delivery

Keywords: morbid obesity labor pain
heart function in patients assessed for sleep apnoea

Conditions: Heart Failure With Preserved Ejection Fraction; Sleep Disordered Breathing; Heart Failure With Normal Ejection Fraction; Obstructive Sleep Apnea; Central Sleep Apnea; Heart Failure

Summary: this study aims to determine the prevalence and prognosis of heart failure with preserved ejection function (hfpef) among patients being assessed for sleep disordered breathing (sdb).

patients with sleep disordered breathing (sdb) and those with heart failure with preserved ejection fraction (hfpef) share similar characteristics. increasing age, hypertension, obesity, diabetes mellitus and atrial fibrillation are well recognised links in both groups. it also known that sdb is common in patients with heart failure, both with reduced and preserved ejection fraction. it is therefore hypothesised that among patients being referred for sdb assessment, we can identify a group with unrecognised hfpef.

Eligibility criteria:
inclusion criteria: * aged ≥40 years and referred for respiratory polygraphy exclusion criteria: * previous diagnosis of heart failure * treated sleep disordered breathing
cerebrospinal fluid proteome in hydrocephalus

Conditions: Normal Pressure Hydrocephalus

Summary: proliphyc is a collaborative prospective study that aims at discovering deep cerebrospinal fluid (csf) proteome with a new clinically-compatible proteomics strategy, in a cohort of 100 patients suspected of neurodegenerative diseases and/or normal pressure hydrocephalus.

csf proteome is the real time protein content that may reveal useful biomarkers for diagnosis and therapeutic decision-making. but the low protein concentration in csf and the low volumes typically obtained after lumbar puncture precludes the conventional use of proteomic analysis. we miniaturized the method to be compatible with low-volume samples by combination of nanolc-ms/ms analysis and combinatorial peptide ligand library technology to reduce the dynamic range of protein concentration in csf and unmask previously undetected proteins. we demonstrated that this deep proteomic analysis allows profiling the csf proteome with a reasonable depth, in short analytical times and good accuracy. we settled a clinically-compatible proteomics strategy targeting the deep csf proteome discovery. the proliphyc study is a prospective study that aims at analysing csf proteome with our new strategy in a cohort of patients suspected of normal pressure hydrocephalus and/or related neurodegenerative diseases. the proliphyc project combines detailed clinical and neuropsychological evaluation, gait analysis, mri brain imaging, lumbar csf dynamics and deep proteome. we hypothesize in the proliphyc study that a specific cluster of polypeptides can be associated with alzheimer disease, vascular dementia and normal pressure hydrocephalus profiles. validating this hypothesis might be a significant step towards a proteomic lexicon of aging brain, neurodegenerative diseases and dementia. neurosciences department and alzheimer disease centre from the toulouse university hospital are both involved in this project. the deep proteomic study is performed in toulouse by the institute of pharmacology and structural biology with the academic support of the institute of mathematics of toulouse.

Eligibility criteria:
inclusion criteria: * gait problems, cognitive decline, urinary incontinence and enlarged ventricles on imaging exclusion criteria: * psychiatric disorders * lumbar punction contraindication * rmi contraindication

Keywords: hydrocephalus proteomic cerebrospinal fluid
pharmacokinetics of voxilaprevir in adults with normal renal function and severe renal impairment

Conditions: HCV Infection

Summary: the primary objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of voxilaprevir (formerly gs-9857) in participants with severe renal impairment and matched healthy control participants.


Eligibility criteria:
key inclusion criteria: * all individuals: * screening laboratory values within defined thresholds for group * use of two effective contraception methods if female of childbearing potential or sexually active male * for individuals with severe renal impairment: * stable chronic kidney disease * creatinine clearance (clcr) \< 30 ml/min key exclusion criteria: * all individuals: * pregnant or nursing female or male with pregnant female partner * hepatitis b virus, hepatitis c virus (hcv) or hiv infection * history of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment or compliance with the protocol * for individuals with severe renal impairment: * anticipated to require dialysis within 90 days of study dosing note: other protocol defined inclusion/exclusion criteria may apply.
safety and efficacy of drug combinations against trichuris trichiura

Conditions: Parasitic Diseases

Summary: this randomised, controlled, double-blinded clinical study investigates the safety and efficacy of albendazole (alb), mebendazole (mbd) and ivermectin (ivm) separately, and alb and mbd each in combination with ivm in the treatment of trichuris trichiura in children aged 5-14 years.


Eligibility criteria:
inclusion criteria: * those who are enrolled in class one to six * are infected with t. trichiura * whose parent consent and who are willing to participate exclusion criteria: * those with acute and chronic diseases other than t. trichiura * those with a history of any serious adverse drug reactions
efficacy of targeted intervention for topical steroid phobia.

Conditions: Dermatologic Disease; Phobia; Adherence, Medication

Summary: topical steroids are an important component of treatment for many dermatological conditions, however 'corticosteroid phobia' is a significant factor contributing to non adherence to prescribed therapy. the primary aim of this study is to determine the effectiveness of targeted education, and involvement in a moderated social forum in reducing steroid phobia as assessed by the topicop© score. secondary objectives include determining if a decrease in topicop© score correlates to an increase in compliance, or an improvement in quality of life.

oral and topical steroids are commonly prescribed in the dermatological setting for its anti inflammatory property, for conditions ranging from eczematous disease, autoimmune disorders and many other primary dermatoses. there is large evidence that topical steroids are safe in the long term when used appropriately, and the benefits of reducing skin inflammation outweigh their risks of skin atrophy and telangiectasia. topical corticosteroid phobia (tcs phobia) toward topical steroids is a significant factor contributing to non adherence. much of this may be attributed to the excessive or exaggerated propagation of 'steroid phobia' messages from the internet, family/friends, and even medical professionals. the topicop© score is the first, and presently only score that is validated to explore tcs phobia. it consists of 12 items assessing three domains of tcs phobia, knowledge and beliefs, fears and behavior. responses are graded with a 4 point likert scale. the primary aim of this study is to determine the effectiveness of targeted education, and involvement in a moderated social forum in reducing steroid phobia as assessed by the topicop© score. secondary objectives include determining if reduction in steroid phobia correlates to an increase in compliance, or an improvement in quality of life. the investigators hypothesise that providing information directed at common misconceptions towards topical steroids will decrease steroid phobia, and that this would result in improved adherence and quality of life. providing access to moderated forums with balanced views and information may also help to address concerns of patients.

Eligibility criteria:
inclusion criteria: participants aged 21 years and above. currently prescribed and expected to be on topical steroids for the next 3 months. willing to provide telephone number or email address, and to be recontacted. able to read and understand english. exclusion criteria: not on topical steroids. unable to understand english. unable or unwilling to be contacted for follow up surveys.

Keywords: steroid phobia topical corticosteroids eczema psoriasis adherence quality of life
rechallenge of imatinib in gist having no effective treatment: right

Conditions: Gastrointestinal Stromal Tumors

Summary: the objective of this study is to compare the clinical outcomes following resumption of dosing (re-challenge) with imatinib plus best supportive care versus placebo plus best supportive care in patients with advanced/incurable gastrointestinal stromal tumors following failure of prior imatinib and sunitinib therapies.


Eligibility criteria:
inclusion criteria: * patients aged 18 years and older * patients with metastatic or unresectable malignant gastrointestinal stromal tumour which has been histologically confirmed by the detection of cd117 on immunohistochemical staining or genetically confirmed by the detection of mutation in kit or pdgfrα genes on direct sequencing of tumor dna. * prior benefit from 1st line imatinib defined as complete response, partial response, or stable disease at 6 months after the start of 1st line imatinib * patients whose disease has progressed despite at least both prior imatinib therapy (400mg/day) and then subsequently also failure of prior sunitinib therapy. * ecog(eastern cooperative oncology group) performance status 0 \~ 3 * adequate bone marrow function as defined by platelets ≥ 75 x 109/l and neutrophils ≥ 1.5 x 109/l * adequate renal function, with serum creatinine \< 1.5 x upper limit of normal * adequate hepatic function with serum total bilirubin \< 1.5 x upper limit of normal, alanine aminotransferase or aspartate aminotransferase \< 2.5 x upper limit of normal in the absence of liver metastases, or \< 5 x upper limit of normal in the presence of liver metastases. * expected life expectancy of greater than 12 weeks in the absence of any intervention * no other malignant disease apart from non-melanotic skin cancer or carcinoma in situ of the uterine cervix or any other cancer except where treated with curative intent \> 5 years previously without evidence of relapse * written, informed consent to the study exclusion criteria: * medical or psychiatric conditions that compromise the patient's ability to give informed consent or to complete the protocol or a history of non- compliance * last dose of radiotherapy received within 4 weeks before the start of study treatment, excluding palliative radiotherapy * obstruction of gastrointestinal tract * active gastrointestinal bleeding * myocardial infarction within 6 months prior to the study medication, and other clinically significant heart disease (e.g., unstable angina, congestive heart failure or uncontrolled hypertension) * evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardise compliance with the protocol * female patients who are pregnant or breast-feeding. female patients must have had a negative pregnancy test within one week before starting imatinib.

Keywords: imatinib re-challenge